1. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
- Author
-
Carol Aghajanian, Lee-may Chen, Scott H. Kaufmann, Amit M. Oza, Geoffrey I. Shapiro, Rebecca Kristeleit, Sandra Goble, Iain A. McNeish, Diane Provencher, Ana Oaknin, Alexandra Leary, Lara Maloney, Elizabeth M. Swisher, Isabelle Ray-Coquard, Howard A. Burris, Stephen Welch, Kevin K. Lin, Tanya Kwan, Ronnie Shapira-Frommer, Anna V. Tinker, David M. O'Malley, Robert L. Coleman, Cancer Research UK, Ovarian Cancer Action, and National Institute for Health Research
- Subjects
Oncology ,Indoles ,ANTITUMOR-ACTIVITY ,MONOTHERAPY ,Loss of Heterozygosity ,DOUBLE-BLIND ,chemistry.chemical_compound ,Ovarian carcinoma ,Aged, 80 and over ,Ovarian Neoplasms ,Clinical Trials, Phase I as Topic ,BRCA1 Protein ,OLAPARIB ,Obstetrics & Gynecology ,Obstetrics and Gynecology ,Structural variant ,Genomics ,Middle Aged ,PARP inhibitor ,SURVIVAL ,RAD51C ,Female ,Safety ,Life Sciences & Biomedicine ,Adult ,medicine.medical_specialty ,CARCINOMA ,Duration of response ,Poly(ADP-ribose) Polymerase Inhibitors ,Clinical Trials, Phase II as Topic ,Internal medicine ,GERMLINE ,Post-hoc analysis ,medicine ,Humans ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Rucaparib ,Aged ,BRCA2 Protein ,Science & Technology ,MUTATIONS ,business.industry ,BRCA1 ,chemistry ,PARP INHIBITOR RUCAPARIB ,Recurrent Ovarian Cancer ,1114 Paediatrics and Reproductive Medicine ,Neoplasm Recurrence, Local ,business ,Recurrent Ovarian Carcinoma ,Follow-Up Studies - Abstract
Objective. To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. Methods. This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), intermediate (6 months to
- Published
- 2021